cdo - highly accurate & objective tests for melanocytic lesions of uncertain malignant potential
Published 2 years ago • 3.9K plays • Length 21:12Download video MP4
Download video MP3
Similar videos
-
50:06
cases with castle biosciences - drazen jukic, m.d., ph.d.
-
29:27
dr. goldberg & dr. cook - diagnostic & prognostic testing in melanocytic lesions
-
48:30
melanoma and the role of personalized medicine: a dermatologist/dermatopathologist’s perspective
-
1:08
the decisiondx®-melanoma test complements current melanoma staging
-
1:16
decisiondx®-melanoma increases the risk prediction that is currently available for patients
-
4:46
decisiondx®-melanoma provides the future of melanoma prognosis for patient, today
-
44:49
dr. goldberg - diagnostic & prognostic testing in melanoma and cutaneous squamous cell carcinoma
-
31:36
dr. moody - advances in cutaneous melanoma
-
49:25
precision oncology: decisiondx®-melanoma and the evolution of gep testing in cutaneous melanoma
-
4:58
decisiondx-um: predicting metastatic risk for early-stage uveal melanoma
-
1:33
new data for decisiondx-melanoma
-
33:01
dermpath on demand: utility of gene expression profiling in melanocytic lesions
-
29:42
castle ask the expert session 1 - understanding genetic testing
-
36:28
overview of melanoma gene expression profile (gep) test by castle biosciences
-
58:50
impact melanoma webinar ondemand
-
33:47
ahns decisiondx–scc webinar: identifying the risk of metastasis in cscc and cscc-hn patients
-
6:22
castle biosciences: changing the way dermatologic cancers are treated and managed